Результаты поиска

Natural Killer Cell Deficiency in Neuroblastoma Amplified Sequence Gene Mutation.

Natural killer cell deficiency (NKD) occurs when decreased levels of such cells lead to major immunological deficiency in the patient. NK cells participate in tumor cell surveillance, viral infections, and immunoregulation in the body. We report a case of a nine-year-old female child, a known case of neuroblastoma amplified sequence (NBAS) gene mutation in the variant c.2819A>C (p. His940Pro), which causes infantile liver failure syndrome type 2 (ILFS2). The patient had been treated at four years of age for a three-day history of vesicular skin rashes in the L2 dermatome of the left leg, with

Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase.

There is much evidence of the importance of the preclinical phase of multiple sclerosis (MS). However, apart from a recent report of the incidental discovery of a case of primary progressive MS, there are no data on the sequential magnetic resonance imaging (MRI) follow-up of patients before the clinical phase. We report the incidental discovery of white matter changes on MRI and their follow-up in a patient three years before the first neurological event (optic neuritis). A 34-year-old woman presented with headaches and depression after her young daughter had been involved in a car accident a

Treatment of mood disorders in multiple sclerosis.

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with a significant comorbidity with depressive diso … Duloxetine may increase liver problems through interaction with these MS treatments: teriflunomide, interferon beta-1a, and interferon beta-1b. Considering psychotherapy, only cognitive behavior therapy and mindfulness-based interventions have shown efficacy in improving depression disorders in MS. A comprehensive treatment for depression should include pharmacother …

Psychotic depression: a peculiar presentation for multiple sclerosis.

Multiple sclerosis (MS) is frequently associated with a number of different psychiatric syndromes. Solely psychiatric syndrome may be the first clinical presentation of multiple sclerosis. We report a patient whose first attack was psychotic depression. The present case emphasizes that psychiatric symptoms can occur at any time during the course of the disease and, moreover, may be the presenting feature.

Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.

Tumefactive demyelinating lesions are a known but uncommon complication of multiple sclerosis, a disease rarely reported in children. This is the case of a 16-year-old African American patient with multiple sclerosis, who developed 2 tumefactive demyelinating lesions. Review of the literature and our own experience helped formulate an algorithm for therapeutic options during an acute attack.

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of the central nervous system. Although subcutaneous administration of interferon (IFN)-β1a is approved as first-line therapy for the treatment of relapsing-remitting MS (RR-MS), its commonly reported adverse events (AEs) such as pain, myalgia, and erythema at the injection site, deeply affect the qua

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

BACKGROUND: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19). METHODS: We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its con…

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine.

INTRODUCTION: Multiple sclerosis (MS) is a long-term autoimmune disease characterized by inflammation and progressive degeneration of the central nervous system. Disease-modifying therapies (DMTs) have proved to be effective at ameliorating the course of MS. DMTs are immunomodulatory drugs affecting immune response to SARS-CoV-2 and its vaccine efficacy in MS patients (pwMS). METHODS: In this longitudinal study, we analyzed T and B cell subsets in peripheral blood and the antigen (spike)-specific T cell response in pwMS patients undergoing interferon β1-a (IFN) or ocrelizumab (OCRE), before a

Долгосрочное лечение с помощью Ocrelizumab у пациентов с ранним восстановлением MS: Nine- Годовые данные исследований OPERA.

ИСТОРИЯ ВОПРОСА И ЦЕЛИ: Пациенты с множественным склерозом (MS) могут продемонстрировать более эффективную борьбу с заболеваниями, когда начинается лечение высокоэффективных методов лечения (ДМТ) с самого начала. В рамках этого подгруппного анализа была проведена оценка долгосрочной эффективности и безопасности высокоэффективного DMT ocrelizumab (OCR) в качестве первой очереди для восстановления MS (RMS). МЕТОДЫ: Постспециальный исследовательский анализ эффективности и безопасности был проведен в подгруппе пациентов, страдающих лечебными расстройствами, с участием РМО, которые получили информа

Glial Fibrilar Acidic Protein как знак болезни в повторном многоразовом склерозе: постспециальный анализ испытаний этапа 3 Ozanimod.

В ходе этого постспециального анализа были изучены взаимосвязи между исходным плазменным фиброзным кислотным белоком (GFAP), потенциальным биомаркером множественного склероза (MS) и базовыми характеристиками и результатами обработки у участников с повторной пощечиной MS (RMS) в ходе двух испытаний этапа 3, в ходе которых случайным образом был присвоен озанимод 0,46 мг или 0,92 мг или интерферон β-1a 30 мкг. МЕТОДЫ: На этапе 3 судебных процессов (SUNBEAM [Clinical Processures.gov: NCT02294058; EudraCT: 2014-002320-27] продолжительность: ≥ 12 месяцев; и RADIANS [Clinical Processors.gov: NCT02047

Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.

BACKGROUND: Pediatric forms of multiple sclerosis are more active than those in adults. Yet, the effectiveness of different therapeutic approaches is not well studied in this population. Our objective was to compare the effectiveness of the early use of high efficacy therapies (HETs) with the effectiveness of moderate efficacy therapies (METs) in children with MS. METHODS: This observational study included patients diagnosed with pediatric MS, at 4 hospital centers in France, during a 10-year period. METs included: interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide; HETs in

Use of multiple sclerosis drugs among pregnant individuals with live-birth deliveries in the FDA's Sentinel Distributed Database.

BACKGROUND: Administrative claims databases may complement pregnancy registries for post-marketing utilization assessment and safety surveillance. OBJECTIVE: To assess patterns of utilization of disease-modifying therapies (DMT) indicated for treatment of multiple sclerosis among women with live-birth deliveries across pregnancy and over time. METHODS: We conducted a retrospective administrative claims-based utilization analysis from January 1, 2001, to December 31, 2020 in the Sentinel Distributed Database. We described use across the pregnancy period and over time among pregnancies ending

A Case of Fingolimod-associated Cryptococcal Meningitis.

BACKGROUND: Leukopenia, a rare adverse effect of Fingolimod therapy, paves the way for opportunistic infections. In this study, we reported rare fingolimod associated cryptococcal meningitis. CASE PRESENTATION: A 39-year-old woman with RRMS was referred to the emergency department. The patient's major complaints were headache, fever, weakness, and progressive loss of consciousness within the last two days prior to the referral. The patient had a history of hospitalization due to RRMS [two times]. In the second hospitalization, interferon Beta-1a was replaced with Fingolimod. Using polymerase …

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.

BACKGROUND: Neutralizing antibodies (NAbs) against interferon beta (IFNβ) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFNβ during 2003-2004 was 32% in a cross-sectional analysis of routine data. OBJECTIVES: The aim of this study was to investigate whether the seroprevalence of NAbs, the levels of NAb titres and the IFNβ preparations used for treatment of multiple sclerosis patients had changed in 2009-2010. METHODS: This study included 1296 patients, analysed for NAbs with the myxovirus resistance p

[Infections and fingolimod].

INTRODUCTION: Fingolimod is the first approved drug with oral availability for the treatment of relapsing multiple sclerosis. AIMS: To revi … ence of higher number of opportunistic and non-opportunistic infections in comparison to placebo or interferon beta-1a in patients receiving fingolimod. However, two patients developed severe herpetic infections under fingolimod. CONCLUSIONS: Fingolimod induce a selective and reversible lymphopenia that, taking into account the most recent available data, does not …

Cutaneous Side-effects of Immunomodulators in MS.

Local skin reactions to subcutaneous injections of interferon beta (IFNB) or glatiramer acetate (GA) in multiple sclerosis (MS) are frequent, while severe cutaneous toxicity is rare. Both IFNB and GA are immunomodulatory drugs that have excellent safety profiles and are currently used for treatment of MS. They are administered by SC injection every other day for IFNB-1b, three times a week for IFNB-1a or daily for 20 mg for GA. The most common adverse effects, which occur in approximately 20-60% of patients, include pain, inflammation and induration at the injection sites. Another adverse effe

Доклад по делу: Долгосрочное подавление рецидивов диметилфумаратом у вновь лечащего педиатра с миэлином олигодендроцитом гликпротеиновым антителным заболеванием, проявляющимся в остром распространении энцетилита, одностороннего оптического невраита и приступов.

Гликопротеиновые заболевания, связанные с антителами (МОГД), которые, как было признано, являются отличительной особенностью у пациентов с расстройствами спектрального спектра нейромиелита, часто являются симптомами острого распространения энцефаломиэлита (АДЕМ) у педиатров. Надлежащее лечение, основанное на точном диагнозе, сопряжено с трудностями при повторном использовании педиатрических пациентов MOGAD. КИСЛОТА: Девушка в возрасте 11 лет четыре раза сталкивалась с рецидивами, вызывая симптомы головного мозга, эпизод ADEM, припадки и оптический неуриит (ON). Первоначально у нее был диагност

Совпадение в аннотации оригинала
BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseases (MOGAD), which has been recognized as a distinct entity i … seizures, and optic neuritis (ON). She was initially diagnosed with multiple sclerosis and received interferon beta-1a therapy with a mild effect on relapse suppression. She was then transferred from the pediatric department to the department of neurology of our hospital. Two months before her referral visit, she experienced left optic neuritis, and her annualized r …

[Clinical course of multiple sclerosis in patients treated with cytostatic drugs for cancer].

INTRODUCTION: The risk of side effects secondary to global and non-specific immune suppression has limited the systematic application of immunosuppressive therapy in multiple sclerosis (MS). However, when a patient with MS develops a cancer, cytostatic drugs as treatment for the neoplastic process may induce improvement not only of the cancer but also of MS. CASE REPORTS: We present a series of four women with clinically defined MS and subjected to cytostatic therapy (cisplatin, 5-fluorouracil, leukovorin, adriamycin, tamoxifen and anastrozole) after the development of cancer: two presented b

Gene Expression Profile of Human Cytokines in Response to Burkholderia pseudomallei Infection.

Melioidosis is an underreported infectious disease, caused by the Gram-negative bacterium Burkholderia pseudomallei. Understanding the disease susceptibility and pathogenesis is crucial for developing newer diagnostic and therapeutic strategies for this life-threatening infection. In this study, we aimed to analyze the gene expression levels of important cytokines in melioidosis patients and establish useful correlates with disease biomarkers compared to cases of sepsis infection caused by other pathogens and healthy individuals. A Qiagen common human cytokines array profiling the gene express

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.

Interferon resistance has been implicated in SARS-CoV-2 escape from innate immunity, but exogenous interferon's impact on viral evolution and diversity is unknown. SNG001, an inhaled interferon-β1a treatment, was evaluated in the ACTIV-2/A5401 randomized controlled trial of therapeutics for COVID-19. We measured viral kinetics and performed whole-genome sequencing on longitudinal nasal swabs collected from ACTIV-2 participants who received either SNG001 or placebo to assess viral sequence diversity. No difference in nasal viral load decay was detected between study arms when stratifying by SAR